Who
Thomas F. Miller
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Iambic Therapeutics; Director, Veracyte.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 Sep 2024
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeutics | SEC FORM 4 Code A | —132,200 at $0.00 | filing |
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code A | —793,200 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —9,321 at $0.00 | filing |
| 3 Sep 2024filed 4 Sep 2024 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —16,507 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.